市場調査レポート

商品コード

1562499

がん免疫療法の市場規模、シェア、成長分析、製品タイプ別、用途別、エンドユーザー別、地域別 - 産業予測、2024年～2031年

Cancer Immunotherapy Market Size, Share, Growth Analysis, By Product Type (Monoclonal Antibodies, Vaccines), By Application (Breast Cancer, Lung Cancer), By End User (Hospitals, Clinics & Others), By Region - Industry Forecast 2024-2031

出版日: 2024年09月13日
発行: SkyQuest
ページ情報: 英文 157 Pages
納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 760,921円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 890,134円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,019,347円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=143.57円

全表示
概要
目次

概要

サンプル依頼リストに入れる

がん免疫療法の世界市場規模は、2022年に1,254億米ドルと評価され、2023年の1,359億3,000万米ドルから2031年には2,591億6,000万米ドルに成長し、予測期間中（2024年～2031年）のCAGRは8.4％で成長すると予測されています。

がん免疫療法の世界市場は、いくつかの重要な要因によって、予測期間中に大きな成長を遂げると予測されています。モノクローナル抗体（mAB）の需要増加や世界の様々なバイオシミラーのイントロダクションと相まって、従来の治療法よりも標的治療へのシフトが市場拡大を促進すると予想されます。これらの革新的な医薬品は、がんと闘うために身体の免疫反応を強化するように設計されており、新しい分子の発見に大きく依存しています。この動向は今後数年間、市場の成長と需要にプラスの影響を与えると予想されます。さらに、市場は米国食品医薬品局（FDA）などの規制機関による承認の拡大からも恩恵を受けるとみられます。例えば、メラノーマや非小細胞肺がん（NSCLC）の治療薬としてPD-1やCTLA-4チェックポイント阻害薬が承認されたことで、市場の成長がさらに促進されると予想されます。特筆すべき例は、アムジェンのルマクラスのFDA承認です。この薬剤は、局所進行性または転移性NSCLCに関連するKRAS G12C変異を有する患者を対象としており、この疾患に対する初の治療薬として画期的な発展を遂げています。このような進歩は、がん免疫療法市場におけるビジネスチャンスの拡大を裏付けています。

市場概要
モノクローナル抗体
- ネイキッドモノクローナル抗体
- 結合モノクローナル抗体
- 二重特異性モノクローナル抗体
ワクチン
- 予防ワクチン
- 治療ワクチン
チェックポイント阻害剤
- 細胞傷害性Tリンパ球関連タンパク質-4（CTLA-4）
- プログラム細胞死1（PD-1）とプログラム細胞死リガンド 1（PD-L1）
細胞療法
- キメラ抗原受容体（CAR）T細胞療法
- 樹状細胞
免疫調節薬
- 顆粒球マクロファージコロニー刺激因子（Gm-CsfおよびG-Csf）
- インターフェロン（IFN）
- インターロイキン（IL）
- 腫瘍溶解性ウイルス
- 免疫療法
- 障害としての免疫
- 味方としての免疫
- 承認製品と臨床試験

がん免疫療法市場：用途別

市場概要
肺がん
乳がん
多発性骨髄腫
大腸がん
頭頸部がん
前立腺がん
悪性黒色腫
その他のがんタイプ

がん免疫療法市場：エンドユーザー別

市場概要
病院
クリニック・その他

がん免疫療法市場規模：地域別

市場概要
北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他欧州地域
アジア太平洋地域
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋地域
ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
中東・アフリカ（MEA）
- GCC諸国
- 南アフリカ
- その他中東・アフリカ地域

競合情勢

上位5社の比較
主要企業の市場ポジショニング（2023年）
主な市場企業が採用した戦略
市場における最近の活動
主要企業の市場シェア（2023年）

主要企業プロファイル

Amgen Inc.（US）
AstraZeneca（UK/Sweden）
Bayer AG（Germany）
Bristol-Myers Squibb（US）
Eli Lilly and Company（US）
Janssen Global Services, LLC（Johnson & Johnson）（US）
Merck & Co., Inc.（US）
Novartis（Switzerland）
Pfizer Inc.（US）
F. Hoffmann-La Roche Ltd（Switzerland）
Gilead Sciences, Inc.（US）
GlaxoSmithKline plc（UK）
AbbVie Inc.（US）
Regeneron Pharmaceuticals, Inc.（US）
Adaptimmune Therapeutics plc（UK）
Incyte Corporation（US）
Bluebird bio, Inc.（US）
BioNTech SE（Germany）
Immunocore Limited（UK）
CureVac N.V.（Germany）
BeiGene, Ltd.（China）
Zymeworks Inc.（Canada）

Product Code: SQMIG35I2296

Global Cancer Immunotherapy Market size was valued at USD 125.4 billion in 2022 and is poised to grow from USD 135.93 billion in 2023 to USD 259.16 billion by 2031, growing at a CAGR of 8.4% during the forecast period (2024-2031).

The global market for cancer immunotherapy is projected to experience significant growth during the forecast period, driven by several key factors. The shift towards targeted therapies over traditional treatments, coupled with the increasing demand for monoclonal antibodies (mABs) and the introduction of various biosimilars worldwide, is expected to propel market expansion. These innovative drugs are designed to enhance the body's immune response to combat cancer, relying heavily on the discovery of new molecules. This trend is anticipated to positively impact market growth and demand in the coming years. Additionally, the market is set to benefit from growing approvals by regulatory bodies such as the U.S. Food and Drug Administration (FDA). For example, the approval of PD-1 and CTLA-4 checkpoint inhibitors for treating melanoma and non-small cell lung cancer (NSCLC) is expected to further drive market growth. A notable instance is the FDA's approval of Amgen's LUMAKRAS. This drug, designed for patients with KRAS G12C mutation associated with locally advanced or metastatic NSCLC, represents a groundbreaking development as it is the first-ever treatment for this condition. Such advancements underscore the expanding opportunities within the cancer immunotherapy market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cancer Immunotherapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cancer Immunotherapy Market Segmental Analysis

Global Cancer Immunotherapy Market is segmented by Product Type, Application, End user, and region. Based on Product Type, the market is segmented into Monoclonal Antibodies, Vaccines, Checkpoint Inhibitors, Cell Therapies, and Immunomodulators. Based on Application, the market is segmented into Lung Cancer, Breast Cancer, Multiple Myeloma, Colorectal Cancer, Head & Neck Cancer, Prostate Cancer, Melanoma, and Other Cancer Types. Based on End user, the market is segmented into Hospitals, and Clinics & Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Drivers of the Global Cancer Immunotherapy Market

The growing preference for immunotherapy over traditional treatments like radiation therapy and chemotherapy is expected to significantly drive the global cancer immunotherapy market in the coming years. Unlike radiation and chemotherapy, which primarily aim to destroy cancer cells through irradiation or surgery, these conventional methods often have the drawback of damaging healthy cells as well. This limitation has led to an increasing shift towards immunotherapy, which works by enhancing the body's own immune system using engineered proteins to target cancer cells more precisely. As a result, hospitals and surgical centers are increasingly adopting immunotherapy treatments due to their potential to reduce side effects and improve patient outcomes. This shift in treatment preference is fostering substantial growth in the global cancer immunotherapy market. By leveraging the body's natural defenses, immunotherapy offers a promising alternative that aligns with the evolving needs of healthcare providers and patients, thereby driving market expansion.

Restraints in the Global Cancer Immunotherapy Market

The high manufacturing costs and elevated prices of cancer immunotherapy treatments are significant factors that may impede the growth of the global market in the forecast period. The development and enhancement of these therapies require substantial resources and significant investment, which can slow market expansion. Additionally, limited medical access in remote and underserved areas, along with geographical barriers, could further restrict the awareness and availability of cancer immunotherapies. These challenges contribute to the slower adoption of these advanced treatments, potentially affecting overall market growth.

Market Trends of the Global Cancer Immunotherapy Market

Ongoing research into drugs designed to minimize side effects is anticipated to stimulate market growth. Additionally, the approval of PD-1 and CTLA-4 checkpoint inhibitors for treating melanoma and Non-Small Cell Lung Cancer (NSCLC) has significantly contributed to the market's expansion. The introduction of new forms of immunotherapy, including vaccines and adjuvants, is further fueling this growth. Moreover, the development and testing of additional immunotherapies, such as immunomodulators and CAR T-cell therapies, are showing promise for improving treatment outcomes. These advancements, coupled with new drug approvals, are expected to drive substantial growth in the cancer immunotherapy market throughout the forecast period.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Technology Analysis
Pricing Analysis
Value Chain Analysis
Ecosystem of the Market
Trade Analysis
Supply chain Analysis
Case study Analysis
Patent Analysis
Customer & Buying Criteria Analysis
Regulatory Landscape
Innovation Matrix
Top Investment Analysis
Key Success Factor
Degree of Competition

Cancer Immunotherapy Market by Product Type

Market Overview
Monoclonal Antibodies
- Naked Monoclonal Antibodies
- Conjugated Monoclonal Antibodies
- Bispecific Monoclonal Antibodies
Vaccines
- Prophylactic Vaccines
- Therapeutic Vaccines
Checkpoint Inhibitors
- Cytotoxic T-Lymphocyte-Associated Protein-4 (CTLA-4)
- Programmed Death 1 (PD-1) & Programmed Death Ligand 1 (PD-L1)
Cell Therapies
- Chimeric Antigen Receptor (CAR) T Cell Therapy
- Dendritic Cells
Immunomodulators
- Granulocyte-Macrophage Colony-Stimulating Factor (Gm-Csf & G-Csf)
- Interferons (IFN)
- Interleukins (IL)
- Oncolytic Virus
- Immunotherapy
- Immunity as an Obstacle
- Immunity as an Ally
- Approved Products & Clinical Trails

Cancer Immunotherapy Market by Application

Market Overview
Lung Cancer
Breast Cancer
Multiple Myeloma
Colorectal Cancer
Head & Neck Cancer
Prostate Cancer
Melanoma
Other Cancer Types

Cancer Immunotherapy Market by End User

Market Overview
Hospitals
Clinics & Others

Cancer Immunotherapy Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Amgen Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca (UK/Sweden)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Janssen Global Services, LLC (Johnson & Johnson) (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Regeneron Pharmaceuticals, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Adaptimmune Therapeutics plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Incyte Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bluebird bio, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioNTech SE (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Immunocore Limited (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CureVac N.V. (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BeiGene, Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Zymeworks Inc. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments